TMC 647055
Alternative Names: TMC-647055Latest Information Update: 05 Nov 2023
At a glance
- Originator Janssen R&D Ireland
- Developer Janssen R&D Ireland; Merck & Co
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 20 Sep 2017 Discontinued - Phase-II for Hepatitis C (Combination therapy) in Belgium (PO)
- 20 Sep 2017 Discontinued - Phase-II for Hepatitis C (Combination therapy) in Germany (PO)
- 20 Sep 2017 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in USA (PO)